证券代码：688203 证券简称：海正生材 公告编号：2023-25 浙江海正生物材料股份有限公司 关于董事会、监事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江海正生物材料股份有限公司（以下简称"公司"）第六届董事会、监事 会任期将于 2023 年 9 月 29 日届满，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《上海证券交易所科创板股票上市规则》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》等法律、法规、规范性文件及 《公司章程》等相关规定，公司已开展董事会、监事会换届选举工作，现将本次 董事会、监事会换届选举情况公告如下： 一、董事会换届选举情况 公司于 2023 年 9 月 5 日召开了第六届董事会第二十七次会议，审议通过了 《关于选举公司第七届董事会非独立董事的议案》、《关于选举公司第七届董事 会独立董事的议案》。经公司董事会提名委员会资格审查，董事会同意提名沈星 虎先生、陈志明先生、王海燕女士、郑华苹女士、陈锡荣先生、薛藩先生及乜君 兴先生为公司第七届 ...

证券代码：688203 证券简称：海正生材 公告编号：2023-23 浙江海正生物材料股份有限公司 关于董事长辞职及收到控股股东推荐函的公告 沈星虎，男，1971 年 11 月出生，法律专业硕士学位。曾任椒江区府办财贸 科科长；台州市椒江区经贸局党委委员、副局长；台州市椒江区海门街道党工委 副书记；台州市椒江区白云街道党工委副书记、办事处主任；台州市椒江区商务 局党委书记、局长；台州市椒江区洪家街道党工委书记；台州大陈岛开发建设管 理委员会党工委委员、副主任，台州市椒江区大陈镇党委书记；台州市椒江区委 常委、区政府党组成员。现任浙江海正集团有限公司党委书记，浙江海正集团有 限公司董事长、法定代表人。 在公司新一届董事会产生前，根据《公司章程》规定，全体董事一致推举董 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2023 年 8 月 31 日，浙江海正生物材料股份有限公司（以下简称"公司"） 董事会收到公司董事长蒋国平先生提交的书面辞职申请，蒋国平先生因个人原因， 经慎重考虑，辞去公司第六届董事会董事、董事长及董事会审计 ...

中信建投证券股份有限公司 关于浙江海正生物材料股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐机构名称：中信建投证券股份有 | 被保荐公司名称：浙江海正生物材料股 | | --- | --- | | 限公司 | 份有限公司 | | | 联系方式：021-68801539 | | 保荐代表人姓名：魏尚骅 | 联系地址：上海市浦东新区浦东南路 | | | 号上海证券大厦北塔 室 528 2203 | | | 联系方式：021-68801539 | | 保荐代表人姓名：张兴华 | 联系地址：上海市浦东新区浦东南路 | | | 号上海证券大厦北塔 室 528 2203 | 经中国证券监督管理委员会《关于同意浙江海正生物材料股份有限公司首次 公开发行股票注册的批复》（证监许可〔2022〕847 号）批准，浙江海正生物材 料股份有限公司（以下简称"公司"或"海正生材"）已于 2022 年 8 月 16 日在上 海证券交易所科创板挂牌上市。本次公司发行新股的发行价为 16.68 元/股，募集 资金总额为 845,167,543.56 元，扣除发行费用 94,306,379.88 元后，实际募集资金 净额为 750 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 333,560,960.24, representing a 10.23% increase compared to CNY 302,617,943.44 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2023 was CNY 19,748,251.69, a decrease of 7.55% from CNY 21,360,228.19 in the previous year[18]. - The net cash flow from operating activities was CNY 79,914,070.51, down 4.78% from CNY 83,921,755.79 in the same period last year[18]. - The basic earnings per share for the first half of 2023 was CNY 0.10, a decrease of 28.57% compared to CNY 0.14 in the same period last year[19]. - The weighted average return on net assets decreased to 1.36%, down 1.85 percentage points from 3.21% in the same period last year[19]. - The net profit after deducting non-recurring gains and losses was CNY 17,625,287.65, a decrease of 7.38% from CNY 19,029,985.66 in the previous year[18]. - The total net assets attributable to shareholders at the end of the reporting period were CNY 1,457,442,561.22, a slight increase of 0.38% from CNY 1,451,881,774.29 at the end of the previous year[19]. - The company reported a decrease in diluted earnings per share to CNY 0.10, down from CNY 0.14 in the same period last year, reflecting the impact of increased share capital post-IPO[19]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 3.76%, up from 2.47% in the previous year, indicating a focus on innovation[19]. - The company achieved a 67.87% increase in R&D expenditures, totaling approximately ¥12.54 million compared to ¥7.47 million in the same period last year[47]. - R&D expenditures accounted for 3.76% of total revenue, an increase of 1.29 percentage points from 2.47% in the previous year[47]. - The company applied for 3 invention patents and 3 utility model patents during the reporting period, bringing the total to 20 invention patents and 5 utility model patents[45]. - The company is focusing on enhancing product optical purity and controlling molecular weight and distribution to improve yield and production efficiency[42]. - The ongoing project for high-purity PLA production has a total investment of ¥22.27 million, with ¥3.89 million invested this period, aiming for a 99% optical purity[49]. - The company is exploring new technological paths to develop greener, functional, and diversified products[42]. Market Position and Products - The company specializes in the research, production, and sales of polylactic acid (PLA), a biodegradable material with significant market potential due to increasing global environmental concerns[26]. - The company has developed a complete commercial production line for PLA, achieving high optical purity and production yield, positioning itself competitively in the international market[27]. - The main product categories include pure PLA and modified PLA, which are tailored for various downstream applications[28]. - The company’s pure PLA is produced using a two-step process, making it a key product that encapsulates most of the company's core technologies[30]. - The company’s product REVODE110 is widely used in low-temperature food contact packaging materials and 3D printing applications[31]. - The company has developed a range of modified polylactic acid products, including REVODE213 for disposable heat-resistant products and REVODE195 for 3D printing materials[33][34]. - The company has developed over 10 main grades and more than 30 sub-grades of polylactic acid (PLA), covering various customer requirements[56]. Environmental Commitment - The company is committed to clean production and compliance with environmental laws, contributing to global sustainable development[100]. - The company has taken carbon reduction measures, including energy conservation and green office practices, although specific CO2 equivalent reductions were not disclosed[101]. - The company has implemented an environmental management system based on ISO14001:2015, enhancing energy and resource utilization while improving environmental performance[100]. - The company has maintained a good operational status for its wastewater treatment facilities, ensuring compliance with pollution discharge standards[97]. - The company’s waste gas emissions from production processes met the required environmental standards, ensuring compliance with national regulations[98]. - The company’s noise emissions complied with the industrial noise emission standards, ensuring minimal impact on the surrounding environment[98]. Financial Risks and Challenges - The competitive landscape has intensified, impacting profit margins due to slow recovery in downstream consumer demand and adjustments in product pricing[41]. - The company faces risks related to supplier concentration, which could impact supply stability and cost if major suppliers encounter difficulties[65]. - The fluctuation in corn prices, a key raw material for PLA production, poses a risk to production costs and market expansion[66]. - The company is experiencing increased competition in the PLA market due to the expansion of production capacity by domestic competitors[67]. - Changes in tax incentive policies could adversely affect the company's profitability if it no longer qualifies for high-tech enterprise tax benefits[72]. - The company is exposed to macroeconomic risks, including uncertainties from international trade policies and potential impacts from geopolitical tensions[73]. Shareholder and Governance Matters - The company has committed to a stock price stabilization plan for three years post-IPO, triggered if the stock price falls below the latest audited net asset value for 20 consecutive trading days[111]. - The company will implement measures to stabilize stock prices if it cannot repurchase shares or if the repurchase proposal is not approved within 10 trading days after triggering conditions are met[111]. - The company has established a commitment to comply with all relevant laws and regulations regarding shareholding and transfer[110]. - The company will limit the transfer of shares by core technical personnel to no more than 25% of their total shares held prior to the IPO each year after the lock-up period[110]. - The company has made commitments regarding the absence of false records or misleading statements in its IPO application documents[114]. - The company will repurchase shares from investors if it violates its commitments and is penalized by regulatory authorities[114]. Future Outlook - The company expects a revenue growth guidance of 20% for the second half of 2023[106]. - New product launches are anticipated to contribute an additional $50 million in revenue by the end of 2023[106]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million allocated for potential deals[106]. - The company plans to increase stock repurchases, with a total amount not less than 20% of the after-tax cash dividends received in the last year[112]. - Future guidance indicates a commitment to increasing production capacity and enhancing product offerings in the biodegradable materials sector[51].

证券代码：688203 证券简称：海正生材 公告编号：2023-21 浙江海正生物材料股份有限公司 关于公司募集资金半年度存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意浙江海正生物材料股份有限公司首 次公开发行股票注册的批复》(证监许可〔2022〕847 号)，本公司由主承销商中 信建投证券股份有限公司采用余额包销方式，向社会公众公开发行人民币普通股 (A 股)股票 5,066.95 万股，发行价为每股人民币 16.68 元，共计募集资金 84,516.75 万元，坐扣承销和保荐费用不含税尾款 6,683.92 万元(保荐承销费共 计人民币7,183.92万元(不含税)，募集资金到位前已预付人民币500.00万元(不 含税))后的募集资金为 77,832.83 万元，已由主承销商中信建投证券股份有限公 司于 2022 年 8 月 11 日汇入本公司募集资金监管账户。另扣除律师费、审计费、 法定 ...

证券代码：688203 证券简称：海正生材 公告编号：2023-22 浙江海正生物材料股份有限公司 第六届监事会第二十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江海正生物材料股份有限公司（以下简称"公司"）第六届监事会第二十 七次会议于 2023 年 8 月 11 日下午在公司会议室以现场方式召开，会议通知已于 2023 年 7 月 31 日以电子邮件方式送达全体监事。会议应出席监事 3 人，实际出 席监事 3 人，会议由监事会主席徐伟先生召集并主持。本次会议的召集、召开程 序和方式符合《公司法》和《公司章程》的有关规定，会议决议合法、有效。经 与会监事审议讨论，本次会议做出如下决议： 一、审议通过《2023 年半年度报告及摘要》 根据相关规定，公司监事会对 2023 年半度报告及摘要进行了审核，审核意 见如下： 2、公司 2023 年半年度报告的内容和格式符合中国证监会和上海证券交易所 的相关规定，公允地反映了报告期内公司的财务状况和经营成果等事项； 3、未发现参与 2023 年半年度报告编制和 ...

浙江海正生物材料股份有限公司（以下简称"公司"）第六届董事会第二十六次会议 审议了《关于公司募集资金半年度存放与实际使用情况的专项报告》，公司董事会已向我 们提交了有关资料，我们在审阅有关资料的同时，就相关问题向公司有关部门和人员进行 了询问。根据《公司章程》及《独立董事工作制度》的规定，基于独立判断，现就上述事 项发表如下独立意见： 《关于公司募集资金半年度存放与实际使用情况的专项报告》真实、准确、完整地反 映了 2023 年上半年公司募集资金的存放、使用与管理情况，募集资金实际使用情况与公 司信息披露情况一致，符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法 律法规的相关规定，不存在违规存放和使用募集资金的行为，亦不存在变相改变募集资金 用途和损害股东特别是中小股东利益的情形。因此，我们同意公司编制的《关于公司募集 资金半年度存放与实际使用情况的专项报告》。 独立董事：王建祥、沈书豪、彭松、刘冉 二〇二三年八月十一日 海正生材独董意见 2023-3 号 浙江海正生物材料股份有限公司独立董事 关于第六届董事会第 ...

证券代码：688203 证券简称：海正生材 公告编号：2023-20 浙江海正生物材料股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 投资者可于 2023 年 08 月 10 日(星期四) 至 08 月 16 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司证券部邮箱 hisunpla@hisunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江海正生物材料股份有限公司（以下简称"公司"）将于 2023 年 8 月 15 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上半年的经营成果、财务状况，公司计划于 2023 年 08 月 17 日下午 15:00-16:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥142,795,235.72, representing a decrease of 18.55% compared to the same period last year[5] - The net profit attributable to shareholders of the listed company was ¥4,160,245.29, down 58.14% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,445,631.20, a decline of 62.71% compared to the previous year[5] - The basic earnings per share for the period was ¥0.02, a decrease of 71.43% year-on-year[6] - Total operating revenue for Q1 2023 was ¥142,795,235.72, a decrease of 18.6% compared to ¥175,316,895.20 in Q1 2022[18] - Net profit for Q1 2023 was ¥4,154,513.72, a decline of 58.2% from ¥9,934,648.54 in Q1 2022[19] - Basic earnings per share for Q1 2023 were ¥0.02, compared to ¥0.07 in Q1 2022, reflecting a 71.4% decrease[20] - The company’s total comprehensive income for Q1 2023 was ¥4,154,513.72, down from ¥9,934,648.54 in Q1 2022[20] Research and Development - The total R&D investment amounted to ¥5,428,464.61, an increase of 75.45% compared to the same period last year[6] - The proportion of R&D investment to operating revenue was 3.80%, up 2.04 percentage points year-on-year[6] - Research and development expenses increased to ¥5,428,464.61 in Q1 2023, up 75.4% from ¥3,094,023.51 in Q1 2022[18] Cash Flow and Liquidity - The net cash flow from operating activities was ¥37,619,112.97, down 15.38% compared to the previous year[6] - Cash flow from operating activities for Q1 2023 was ¥37,619,112.97, down 15.4% from ¥44,455,687.69 in Q1 2022[23] - The company recorded a net cash outflow from investing activities of -¥71,787,756.77 in Q1 2023, compared to -¥56,216,787.63 in Q1 2022[23] - The net cash flow from financing activities was -$3,675,969.36, indicating a significant outflow compared to the previous period's -$15,395,767.99[24] - The total cash and cash equivalents at the end of the period decreased to $879,323,074.53 from $917,893,087.61 at the beginning of the period, reflecting a net decrease of $38,570,013.08[24] - The impact of exchange rate changes on cash and cash equivalents was -$725,399.92, which is a notable change from -$302,573.33 in the previous period[24] Assets and Liabilities - Total assets at the end of the period were ¥1,972,695,944.93, an increase of 2.34% from the end of the previous year[6] - As of March 31, 2023, the total assets amounted to CNY 1,972,695,944.93, an increase from CNY 1,927,583,851.08 as of December 31, 2022, reflecting a growth of approximately 2.3%[15] - The total current assets decreased to CNY 1,074,838,907.36 from CNY 1,102,374,248.64, representing a decline of about 2.5%[16] - The company's cash and cash equivalents stood at CNY 896,119,710.09, down from CNY 938,487,988.19, indicating a decrease of approximately 4.5%[15] - The total liabilities increased to CNY 516,648,127.34 from CNY 475,690,547.21, marking an increase of about 8.6%[17] - The company's equity increased to CNY 1,456,047,817.59, up from CNY 1,451,893,303.87, showing a slight growth of approximately 0.3%[17] - The accounts receivable rose significantly to CNY 31,352,219.98 from CNY 8,302,121.89, reflecting an increase of approximately 277%[15] - Inventory decreased to CNY 122,027,995.45 from CNY 135,942,269.61, indicating a decline of about 10.3%[16] - The company reported a total of CNY 348,733,155.86 in current liabilities, an increase from CNY 307,370,843.59, which is an increase of approximately 13.5%[17] - The long-term borrowings remained stable at CNY 127,170,513.00, slightly down from CNY 127,314,504.50, showing a decrease of about 0.1%[17] - The company’s retained earnings increased to CNY 41,912,462.43 from CNY 37,752,217.14, reflecting a growth of approximately 11.4%[17] Operating Costs - Total operating costs for Q1 2023 were ¥135,987,052.05, down 16.6% from ¥163,128,824.90 in Q1 2022[18]

证券代码：688203 证券简称：海正生材 公告编号：2023-13 浙江海正生物材料股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 16 日(星期四) 至 03 月 22 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司证券部邮箱 hisunpla@hisunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江海正生物材料股份有限公司（以下简称"公司"）已于 2023 年 3 月 14 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 03 月 23 日下午 15:00-16:00 举 行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 ...